Fausto Barbieri

A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.

G. Scagliotti, F. Cappuzzo, S. Novello, 2006, Lung cancer.

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

G. Scagliotti, A. Ceribelli, S. Novello, 2005, British Journal of Cancer.

Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer

M. Brausi, F. Barbieri, V. Silingardi, 1991, Medical oncology and tumor pharmacotherapy.